The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study.
 
Fumiya Hongo
Honoraria - Merck
Consulting or Advisory Role - Merck
Speakers' Bureau - Merck; MSD; Pfizer; Takeda
 
Yasutomo Nakai
No Relationships to Disclose
 
Masahiro Nozawa
No Relationships to Disclose
 
Taigo Kato
Honoraria - Bristol-Myers Squibb Japan; Merck; MSD; Pfizer; Takeda
Research Funding - Takeda
 
Sadanori Kamikawa
No Relationships to Disclose
 
Satoshi Tamada
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD; Takeda
 
Kaori Yamada
Honoraria - Takeda
 
Junpei Soeda
Employment - Takeda
 
Ryoichi Tsubouchi
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Tsuyoshi Osaka
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Hirotsugu Uemura
Honoraria - Bristol-Myers Squibb Japan; Janssen; Takeda pharm.
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Eisai; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)